BACKGROUND: Revision arthroplasty surgery is often complicated by loss of bone stock that can be managed by the use of bone allograft. The allograft provides immediate stability for the revision implant but may be resorbed, impairing subsequent implant stability. Bisphosphonates can delay allograft resorption. We hypothesized that zoledronate-impregnated allograft impacted around revision implants would improve implant fixation as characterized by mechanical push-out testing and histomorphometry. METHODS: Twenty-four axially pistoning micromotion devices were inserted bilaterally into the knees of twelve dogs according to our revision protocol. This produced a standardized revision cavity with a loose implant, fibrous tissue, and a sclerotic bone rim. Revision surgery was performed eight weeks later; after stable titanium revision components were implanted, saline solution-soaked allograft was impacted around the component on the control side and allograft soaked in 0.005 mg/mL zoledronate was impacted on the intervention side. The results were evaluated after four weeks. RESULTS: The zoledronate treatment resulted in a 30% increase in ultimate shear strength (p = 0.023), a 54% increase in apparent shear stiffness (p = 0.002), and a 12% increase in total energy absorption (p = 0.444). The quantity of allograft in the gap was three times greater in the zoledronate group compared with the control group (p < 0.001). The volume fraction of new bone in the zoledronate group (25%; 95% confidence interval [CI], 22% to 28%) was similar to that in the control group (23%; 95% CI, 19% to 26%) (p = 0.311). CONCLUSIONS: The data obtained in this canine model suggest that pretreating allograft with zoledronate may be beneficial for early stability of grafted revision arthroplasty implants, without any adverse effect on bone formation. Clinical studies are warranted. CLINICAL RELEVANCE: The zoledronate treatment is simple to apply in the clinical setting. The treatment could increase early stability of revision joint replacements without impairing new bone formation. In the long term, this can potentially improve the longevity of revision joint replacements and reduce the number of subsequent revisions.
BACKGROUND: Revision arthroplasty surgery is often complicated by loss of bone stock that can be managed by the use of bone allograft. The allograft provides immediate stability for the revision implant but may be resorbed, impairing subsequent implant stability. Bisphosphonates can delay allograft resorption. We hypothesized that zoledronate-impregnated allograft impacted around revision implants would improve implant fixation as characterized by mechanical push-out testing and histomorphometry. METHODS: Twenty-four axially pistoning micromotion devices were inserted bilaterally into the knees of twelve dogs according to our revision protocol. This produced a standardized revision cavity with a loose implant, fibrous tissue, and a sclerotic bone rim. Revision surgery was performed eight weeks later; after stable titanium revision components were implanted, saline solution-soaked allograft was impacted around the component on the control side and allograft soaked in 0.005 mg/mL zoledronate was impacted on the intervention side. The results were evaluated after four weeks. RESULTS: The zoledronate treatment resulted in a 30% increase in ultimate shear strength (p = 0.023), a 54% increase in apparent shear stiffness (p = 0.002), and a 12% increase in total energy absorption (p = 0.444). The quantity of allograft in the gap was three times greater in the zoledronate group compared with the control group (p &lt; 0.001). The volume fraction of new bone in the zoledronate group (25%; 95% confidence interval [CI], 22% to 28%) was similar to that in the control group (23%; 95% CI, 19% to 26%) (p = 0.311). CONCLUSIONS: The data obtained in this canine model suggest that pretreating allograft with zoledronate may be beneficial for early stability of grafted revision arthroplasty implants, without any adverse effect on bone formation. Clinical studies are warranted. CLINICAL RELEVANCE: The zoledronate treatment is simple to apply in the clinical setting. The treatment could increase early stability of revision joint replacements without impairing new bone formation. In the long term, this can potentially improve the longevity of revision joint replacements and reduce the number of subsequent revisions.
Authors: Thomas Jakobsen; Jørgen Baas; Joan E Bechtold; Brian Elmengaard; Kjeld Søballe Journal: Clin Orthop Relat Res Date: 2007-10 Impact factor: 4.176
Authors: Steven Kurtz; Fionna Mowat; Kevin Ong; Nathan Chan; Edmund Lau; Michael Halpern Journal: J Bone Joint Surg Am Date: 2005-07 Impact factor: 5.284
Authors: Jorgen Baas; Brian Elmengaard; Thomas B Jensen; Thomas Jakobsen; Niels T Andersen; Kjeld Soballe Journal: Biomaterials Date: 2008-04-14 Impact factor: 12.479